Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › vincristine

vincristine

16 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of vincristine

181 trials tracked of vincristine: 46 in phase 3 or 4 and 26 with published results. The most-cited published study has 721 citations.

181Trials tracked
46Phase 3 & 4
0Recruiting
26With published results
Phase distribution
Phase 4 1 Phase 3 45 Phase 2 114 Phase 1 12 Other / NA 9
  1. Phase 3 ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas Completed · 721 cited
  2. Phase 3 A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma Completed · 612 cited
  3. Phase 3 Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma Completed · 421 cited
  4. Phase 3 SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma Completed · 341 cited
  5. Phase 3 Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma Completed · 268 cited
  6. Phase 3 Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Completed · 248 cited
Show 44 more trials
  1. Phase 3 05-001: Treatment of Acute Lymphoblastic Leukemia in Children Completed · 238 cited
  2. Phase 3 Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Completed · 226 cited
  3. Phase 3 Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma Completed · 198 cited
  4. Phase 3 Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma Completed · 174 cited
  5. Phase 3 Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor Completed · 116 cited
  6. Phase 3 Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma Completed · 100 cited
  7. Phase 3 Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma Completed · 98 cited
  8. Phase 3 Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations Completed · 84 cited
  9. Phase 3 To Demonstrate Equivalence of Pharmacokinetics and Noninferiority of Efficacy for CT-P10 in Comparison With Rituxan Completed · 75 cited
  10. Phase 3 Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma Completed · 57 cited
  11. Phase 3 Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma Completed · 49 cited
  12. Phase 3 Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia Completed · 48 cited
  13. Phase 3 Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia Completed · 46 cited
  14. Phase 3 Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Completed · 36 cited
  15. Phase 3 A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM) Completed · 32 cited
  16. Phase 3 A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma Completed · 25 cited
  17. Phase 3 Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor Completed · 20 cited
  18. Phase 3 Combination Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Lymphoma Completed · 17 cited
  19. Phase 3 Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma Completed · 15 cited
  20. Phase 3 Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System Completed · 7 cited
  21. Phase 4 An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma Completed
  22. Phase 3 Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma Completed
  23. Phase 3 A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) Completed
  24. Phase 3 Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients Completed
  25. Phase 3 Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma Completed
  26. Phase 3 MabionCD20 Compared to MabThera in Lymphoma Patients Completed
  27. Phase 3 Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A Completed
  28. Phase 3 A Study of Rituximab (MabThera) Subcutaneous (SC) Versus Rituximab (MabThera) Intravenous in Participannts With Follicular Non-Hodgkin's Lymphoma Completed
  29. Phase 3 Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia Completed
  30. Phase 3 Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma Completed
  31. Phase 3 Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma Completed
  32. Phase 3 Combination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma Completed
  33. Phase 3 High-Dose Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Metastatic Rhabdomyosarcoma or Ectomesenchymoma Completed
  34. Phase 3 Comparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell Lymphoma Completed
  35. Phase 3 Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor Completed
  36. Phase 3 Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study Completed
  37. Phase 3 UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy Completed
  38. Phase 3 Neoadjuvant Carboplatin and Vincristine and Standard Local Ophthalmic Therapy in Treating Patients With Intraocular Retinoblastoma Completed
  39. Phase 3 Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or Lymphoma Completed
  40. Phase 3 S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma Completed
  41. Phase 2 Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Newly Diagnosed Large B-Cell Lymphoma Completed
  42. Phase 2 Evaluate PKs and Efficacy Assessment of Palifermin in Patients With Sarcoma Completed
  43. Phase 2 Vincristine Sulfate, Topotecan Hydrochloride, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma Completed
  44. Phase 2 Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia Completed

Showing the 50 most-cited and recently-updated of 181 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Reduced-dose craniospinal radiation and smaller volume boost for medulloblastoma patients
Pediatrics Phase III
Reduced-dose craniospinal radiation and smaller volume boost for medulloblastoma patients Trial Shows Reduced Radiation May Help Children With Medulloblastoma
This randomized phase 3 trial evaluated reduced-dose craniospinal radiation (18.00 Gy) and a smaller volume boost in children aged 3 to 7 wi…
A large clinical trial looked at whether reducing radiation doses for children with medulloblastoma can maintain safety and effectiveness.
CT.gov Jun 10, 2026
Pleuropulmonary blastoma diagnosed after initial rhabdomyosarcoma interpretation in a 2-year-old boy
Pediatrics Sys. Review
Pleuropulmonary blastoma diagnosed after initial rhabdomyosarcoma interpretation in a 2-year-old boy Case report shows rare lung cancer in toddler with DICER1
This case report describes a 2-year-old boy with a thoracic mass initially interpreted as embryonal rhabdomyosarcoma, later diagnosed as ple…
A toddler’s lung tumor was reclassified as a rare cancer linked to DICER1 syndrome, changing his treatment and highlighting a key diagnosis …
Frontiers Jun 5, 2026
Interval-compressed VDC/IE protocol feasibility and outcomes in 27 Ewing's sarcoma patients at a North African center
Oncology Cohort
Interval-compressed VDC/IE protocol feasibility and outcomes in 27 Ewing's sarcoma patients at a North African center Compressed chemotherapy showed mixed results for Ewing's sarcoma patients in a small study.
This retrospective, single-institutional cohort study evaluated an interval-compressed VDC/IE protocol in 27 patients with Ewing's sarcoma t…
A small study found that a compressed chemotherapy regimen for Ewing's sarcoma had high toxicity and low survival rates.
Frontiers Jun 4, 2026
Attenuated R-THP-COP regimen achieved complete response in an 85-year-old with diffuse large B-cell lymphoma
Oncology Sys. Review
Attenuated R-THP-COP regimen achieved complete response in an 85-year-old with diffuse large B-cell lymphoma Attenuated R-THP-COP regimen shows promise for elderly diffuse large B-cell lymphoma
This case report describes an 85-year-old female patient with diffuse large B-cell lymphoma treated with an attenuated R-THP-COP regimen. Th…
An 85-year-old woman achieved complete radiological response and remained symptom-free for three years on an attenuated chemotherapy regimen…
Frontiers Jun 2, 2026
Review discusses pharmacogenomic biomarkers for pediatric B-ALL chemotherapy dosing
Drug Pipeline Sys. Review
Review discusses pharmacogenomic biomarkers for pediatric B-ALL chemotherapy dosing New review looks at using genetic tests to adjust cancer drug doses for kids
This narrative review examines the role of pharmacogenomic biomarkers and genotype-guided dose adjustments in pediatric B-cell acute lymphob…
A recent review suggests that checking specific genes before treatment can help doctors give the right amount of chemotherapy to children wi…
Frontiers May 24, 2026
Case report of 3-year-old girl with bilateral Wilms tumor and TP53 mutation treated with VAD chemotherapy and surgery
Pulmonology & Critical Care Sys. Review
Case report of 3-year-old girl with bilateral Wilms tumor and TP53 mutation treated with VAD chemotherapy and surgery 3-year-old girl with TP53 mutation and bilateral Wilms tumor died after treatment
This case-based review describes a single 3-year-old girl with bilateral Wilms tumor and a TP53 mutation treated under the Chinese Children …
A single case report describes a 3-year-old girl with bilateral Wilms tumor and a TP53 mutation who died despite aggressive chemotherapy and…
Frontiers May 22, 2026
Meta-analysis of double-expressor lymphoma prognoses and novel therapies
Infectious Disease Meta-analysis
Meta-analysis of double-expressor lymphoma prognoses and novel therapies Double-expressor lymphoma linked to worse survival outcomes in large study
This systematic evaluation meta-analysis of 9,808 patients with diffuse large B-cell lymphoma found double-expressor lymphoma (DEL) is assoc…
A major review finds double-expressor lymphoma patients have worse survival. New drug combinations show promise for better results.
Frontiers May 22, 2026
Tucidinostat plus R-CHOP improves outcomes in MYC/BCL2 double-expressor DLBCL
Oncology RCT
Tucidinostat plus R-CHOP improves outcomes in MYC/BCL2 double-expressor DLBCL New drug tucidinostat improves outcomes for high-risk lymphoma patients
A phase 3 trial found adding oral tucidinostat to R-CHOP significantly improved event-free survival and complete response rates in patients …
A large trial shows adding tucidinostat to standard chemo lowers disease risk and improves survival for patients with aggressive lymphoma.
JAMA May 19, 2026
Ibrutinib plus chemo without ASCT shows survival benefit in mantle cell lymphoma
Oncology RCT
Ibrutinib plus chemo without ASCT shows survival benefit in mantle cell lymphoma Adding stem cell transplant to ibrutinib treatment offered no extra benefit for lymphoma patients
In younger patients with mantle cell lymphoma, adding ASCT to an ibrutinib regimen did not improve outcomes but increased toxicity. Ibrutini…
Adding stem cell transplant to ibrutinib did not improve survival for younger lymphoma patients but increased side effects.
May 16, 2026
Meta-analysis links vincristine and other drugs to higher cisplatin hearing loss risk in pediatric cancer
ENT (Otolaryngology) Meta-analysis
Meta-analysis links vincristine and other drugs to higher cisplatin hearing loss risk in pediatric cancer Hidden Danger in Kids' Cancer Treatment Raises Hearing Loss Risk
This meta-analysis of observational studies synthesized evidence on concomitant medications and cisplatin-induced hearing loss in pediatric …
• Four common drugs nearly quadruple hearing damage during chemo • Helps oncologists protect children from silent treatment side effects • D…
Frontiers May 14, 2026
UK trial reports 4-year event-free survival of 63% and overall survival of 68% in relapsed Wilms tumour patients
Pediatrics
UK trial reports 4-year event-free survival of 63% and overall survival of 68% in relapsed Wilms tumour patients High-dose chemo plus stem cell rescue offers hope for relapsed Wilms tumour
This clinical trial report evaluates outcomes for 78 children with relapsed or refractory Wilms tumour treated in the United Kingdom.
A UK trial found that a risk-stratified protocol with high-dose melphalan and stem cell rescue helped some children with relapsed Wilms tumo…
May 1, 2026
Exploratory RCT finds in situ vaccine plus PD-1 with immunoradiotherapy shows response in advanced hepatic malignancies
Oncology RCT
Exploratory RCT finds in situ vaccine plus PD-1 with immunoradiotherapy shows response in advanced hepatic malignancies New Vaccine Combo Shrinks Liver Tumors Safely
An exploratory RCT of 18 patients with advanced hepatic malignancies compared in situ vaccine FOLactis plus PD-1 antibody combined with eith…
A new vaccine combo shrinks liver tumors safely without the severe side effects usually caused by strong cancer drugs.
Apr 12, 2026

All vincristine Articles